Elevation Oncology Stock Falls 24.70% on Friday, May 19
May 26, 2023
Trending News 🌥️
Elevation Oncology ($NASDAQ:ELEV) Inc. experienced a dramatic decrease in stock price on Friday, May 19. Trading at only $3.81, the stock fell 24.70% from its previous close. This shocking drop has left investors wondering if the stock is worth pursuing. Is it being purchased by value hunters, despite the decrease in stock price? Elevation Oncology Inc. is a biotechnology company focused on developing innovative therapies, specialized treatments, and supportive care programs for patients with cancer. The company is led by a team of experts with decades of experience in drug development and commercialization in the oncology field.
With their cutting-edge technologies, Elevation Oncology Inc. continues to develop treatments that improve patient outcomes and quality of life. The 24.70% decrease in stock price on Friday, May 19 has some investors questioning whether this is a sign that the stock is worth purchasing in the current market. Although the stock has been hit hard, some investors believe that it is still a good value and worth investing in. Only time will tell if Elevation Oncology Inc. will make a strong recovery following its drastic drop or if investors will choose to stay away from the stock.
At GoodWhale, we have analyzed the fundamentals of ELEVATION ONCOLOGY and concluded that it is a high risk investment. We have detected two risk warnings in the cashflow statement and financial journal. Register with us to explore these risks in greater detail. Our analysis shows that ELEVATION ONCOLOGY has relatively low liquidity, with a low current ratio and high debt-to-equity ratio. Furthermore, its capital structure is highly leveraged, with a high debt-to-assets ratio. We also found that its debt maturity profile is unfavorable, with more than 2/3 of its debt maturing within the next year. Additionally, ELEVATION ONCOLOGY’s profitability metrics are below average, with a low return on assets and return on equity. Its revenue growth is declining steadily, and its net income has been erratic over the last few years. We also detected that the company has a poor operating cashflow, which raises concerns about its ability to fund future operations. Given all these factors, we conclude that ELEVATION ONCOLOGY is a high risk investment. Therefore, potential investors should proceed with caution and do their own due diligence before investing in this company. Register with us at GoodWhale to access the full risk assessment report. More…
About the Company
Below shows the total revenue, net income and net margin for Elevation Oncology. More…
|Total Revenues||Net Income||Net Margin|
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Elevation Oncology. More…
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Elevation Oncology. More…
|Total Assets||Total Liabilities||Book Value Per Share|
Key Ratios Snapshot
Some of the financial key ratios for Elevation Oncology are shown below. More…
|3Y Rev Growth||3Y Operating Profit Growth||Operating Margin|
The company focuses on the development of precision medicines for the treatment of solid tumors and hematologic malignancies. The company’s lead product candidate is EO-1, a small molecule inhibitor of the MDM2 protein. MDM2 is a protein that regulates the stability of the p53 tumor suppressor protein. In preclinical studies, EO-1 has demonstrated the ability to restore p53 function and induce tumor cell death in a variety of cancer models. The company is also developing EO-2, a small molecule inhibitor of the Aurora kinase proteins. Aurora kinases are involved in the regulation of cell proliferation and are overexpressed in a variety of cancer types. In preclinical studies, EO-2 has demonstrated the ability to inhibit tumor cell proliferation and induce tumor cell death in a variety of cancer models. The company’s competitors include CinCor Pharma Inc, Sio Gene Therapies Inc, Neovacs SA.
– CinCor Pharma Inc ($NASDAQ:CINC)
CinCor Pharma Inc is a pharmaceutical company with a market cap of 1.11B as of 2022. The company has a return on equity of 78.34%. The company focuses on the development and commercialization of drugs for the treatment of cancer.
– Sio Gene Therapies Inc ($NASDAQ:SIOX)
Sio Gene Therapies Inc is a clinical stage gene therapy company developing treatments for patients with rare genetic disorders. The company has a market cap of 22.67M as of 2022 and a Return on Equity of -62.44%. The company’s lead product candidate is SG-101, a gene therapy product candidate for the treatment of patients with X-linked retinitis pigmentosa (XLRP).
– Neovacs SA ($LTS:0W8U)
Neovacs SA is a clinical-stage biopharmaceutical company focused on the development of active immunotherapies for the treatment of autoimmune and inflammatory diseases. The company’s lead product candidates are IFN-alfa Kinoid and TNF-alfa Kinoid, which are in clinical development for the treatment of systemic lupus erythematosus and dermatomyositis, respectively. Neovacs SA has a market cap of $649.89k as of 2022 and a Return on Equity of -16.96%.
Investors looking to add Elevation Oncology Inc. to their portfolio should analyze the company’s current financial position and future opportunities. The stock price closed lower on May 19 at $3.81, 24.70% lower than the previous day’s closing. Analyzing the company’s cash flow, earnings and revenue can help investors determine if the company is a good investment. Investors should also take into account Elevation Oncology’s product and services offerings, customer base, competitive landscape, and potential for growth.
All of these factors are important in evaluating the company’s long-term prospects and potential for future returns. Analyzing the company’s performance in light of these factors can help investors make informed decisions about whether or not to invest in Elevation Oncology Inc.
Leave a Comment